Alphamab Co. Ltd was established in early 2008 by Dr. Ting Xu. Since its inception, the company has been striving to become a leader in booming biotech industry in China.

    The R&D center in Suzhou occupies over 60,000 square feet lab and office space. Now the center has over 100 talented scientists, more than 60% of which hold graduate degrees. In past few years, Alphamab has formed strategic alliance with Shanghai Institute of Materia Medica, Chinese Academy of Science, Southeast University and Thermo Scientific as part of its open drug discovery platform. The platform is supported by a world class scientific advisory board and active collaborations with major pharmaceutical companies in China. So far, over 300M RMB has been invested in infrastructure and advanced instruments. The center is fully equipped for biologics R&D, from target validation, hit screening, H2L, PK/PD, pharmacology, cell line construction, process development, scale up pilot manufacturing. Currently there are more than 30 active projects in Alphamab, including biosimilars, novel mAbs and engineered version of mAbs and proteins. Through internal effort and external collaboration, Alphamab is successfully entering , entering hematology, endocrinology and anti-infection area.